Aurobindo Pharma share news, announcements and annual reports
NSE: AUROPHARMABSE: 524804Pharmaceuticals & BiotechnologyMid Cap
Aurobindo Pharma Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995 on BSE, Jul 2000 on NSE
Last close ₹1,683.80up ₹2.40 (0.14%)BSE ₹1,685.00
Share price at the NSE close on 2 Nov 2026. Previous close ₹1,681.40.
2 Nov: open ₹1,688.90, high ₹1,688.90, low ₹1,660.50
52-week range of traded prices to 2 Nov 2026
₹1,106.00Low, 10 Feb 2026₹1,740.00High, 24 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results and dividend. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹96,882 Cr138th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.10
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.56
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 10.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.20
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 7,38,10850.3% delivered
Aurobindo Pharma share news and announcements
1,689 announcements, routine notices left out, newest first. Page 19 of 34.
Aug 2017
23 Aug · Analysts
21 Aug · Analysts
17 Aug · Analysts
9 Aug · Results
5 Aug · Analysts
Jul 2017
Jun 2017
7 Jun · Analysts
May 2017
30 May · Corporate action
29 May · Board meeting
29 May · Results
20 May · Analysts
Apr 2017
19 Apr · Legal
Exchange has sought clarification from the Company with respect to recent news item captioned "US FDA Issues 5-6 'Largely Procedural' Observations To Aurobindo Pharma's Unit-III". In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.
Mar 2017
30 Mar · Disclosure
28 Mar · Business
20 Mar · Business
9 Mar · Disclosure
Feb 2017
23 Feb · Analysts
9 Feb · Business
9 Feb · Management
9 Feb · Business
9 Feb · Results
6 Feb · Analysts
Jan 2017
17 Jan · Analysts
9 Jan · Analysts
7 Jan · Business
7 Jan · Business
Dec 2016
16 Dec · News Verification
Exchange has sought clarification from Aurobindo Pharma Limited with respect to recent news item captioned "US States sue 6 Pharma Cos." In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.